Sermonix Pharma Using Guardant Health CDx to Screen Breast Cancer Patients for Lasofoxifene Trial
The ELAINE-3 study, a Phase III trial, will use the Guardant360 CDx liquid biopsy test to screen patients for ESR1 mutations.
Immune Signatures Outperform TILs for HER2-Positive Breast Cancer Prognoses
Immune-related gene expression signatures tracked more closely with treatment response and outcomes than tumor-infiltrating lymphocytes in early-stage HER2-positive breast cancer.
Breast Cancer Genomic Recurrence Signature Influenced by BMI in Young Patients
In younger Korean women with estrogen receptor-positive, HER2/ERBB2-negative breast cancer, higher body mass index appeared to coincide with a higher Oncotype Dx recurrence score.
Guardant Health, Thermo Fisher Scientific Tests Approved as CDx to Enhertu in Lung Cancer
The tests can now be used to identify patients with specific HER2-activating mutations that sensitize their tumors to the newly approved antibody-drug conjugate.
Agendia Building Validation Data on ImPrint for Guiding Neoadjuvant Immunotherapy in Breast Cancer
The firm envisions marketing the 53-gene signature with its existing MammaPrint and BluePrint tests as a comprehensive platform for breast cancer treatment selection.